Published in Lancet on September 07, 2008
Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes | NCT02380521
Exenatide Once-weekly as a Treatment for Multiple System Atrophy (MSA) | NCT04431713
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 5.57
Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol (2009) 3.43
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov (2009) 3.26
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 2.59
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol (2009) 1.77
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open (2013) 1.65
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes (2009) 1.65
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care (2011) 1.63
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care (2011) 1.61
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther (2011) 1.57
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care (2013) 1.51
Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes (2013) 1.49
Incretin-based therapies. J Diabetes (2012) 1.48
Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes. J Diabetes Sci Technol (2015) 1.43
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes (2010) 1.43
Novo awaits green light for diabetes drug. Nat Biotechnol (2009) 1.39
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis (2010) 1.36
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care (2009) 1.34
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
Liraglutide. Nat Rev Drug Discov (2010) 1.27
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab (2013) 1.22
Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care (2009) 1.22
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab (2012) 1.20
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol (2010) 1.17
Impact of postprandial glycaemia on health and prevention of disease. Obes Rev (2012) 1.17
GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab (2015) 1.15
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab (2016) 1.15
Hydrogel drug delivery system with predictable and tunable drug release and degradation rates. Proc Natl Acad Sci U S A (2013) 1.15
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord (2010) 1.14
Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care (2013) 1.13
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med (2011) 1.12
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res (2011) 1.12
Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc (2010) 1.09
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. Diabetes Technol Ther (2015) 1.09
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ (2010) 1.08
The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med (2009) 1.08
Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med (2009) 1.08
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care (2014) 1.07
Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol (2010) 1.06
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord (2011) 1.04
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care (2012) 1.04
Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) (2013) 1.04
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes (2013) 1.02
GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab (2012) 1.01
Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev (2013) 1.00
GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab (2011) 0.99
Action and therapeutic potential of oxyntomodulin. Mol Metab (2013) 0.98
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig (2012) 0.98
Type 2 diabetes mellitus--current therapies and the emergence of surgical options. Nat Rev Endocrinol (2011) 0.97
Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci (2014) 0.97
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol (2010) 0.97
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol (2015) 0.97
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care (2012) 0.95
Obesity treatment: novel peripheral targets. Br J Clin Pharmacol (2009) 0.95
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol (2009) 0.95
Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev (2014) 0.94
Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract (2012) 0.94
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) (2012) 0.93
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context (2015) 0.93
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther (2011) 0.93
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab (2015) 0.93
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid (2010) 0.92
Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag (2009) 0.92
Incretin agents in type 2 diabetes. Can Fam Physician (2010) 0.92
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med (2013) 0.91
Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig (2014) 0.91
Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes Obes Metab (2012) 0.91
Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proc Natl Acad Sci U S A (2012) 0.91
Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol (2012) 0.90
Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. Mayo Clin Proc (2010) 0.89
Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. Mayo Clin Proc (2010) 0.89
The gut hormones in appetite regulation. J Obes (2011) 0.88
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes (2015) 0.88
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther (2015) 0.88
Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol (2014) 0.88
Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study. Diabetes Metab J (2012) 0.88
Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther (2012) 0.87
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab (2012) 0.87
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLoS One (2015) 0.86
The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis (2014) 0.86
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes (Lond) (2013) 0.86
GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci (2015) 0.86
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag (2012) 0.86
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol (2013) 0.86
Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther (2015) 0.85
Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One (2013) 0.85
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. Rev Diabet Stud (2009) 0.85
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care (2012) 0.85
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Open Med Chem J (2011) 0.84
Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res (2012) 0.84
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol (2013) 0.84
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest (2014) 0.84
The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. PLoS One (2015) 0.84
Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Drive onto Mesolimbic Dopamine Neurons. Cell Rep (2015) 0.84
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab (2015) 0.84
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet (2010) 4.89
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet (2012) 3.48
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 2.96
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.15
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care (2007) 2.14
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 2.12
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2005) 2.04
Assessment of group versus individual diabetes education: a randomized study. Diabetes Care (2002) 2.02
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Consensus report of the coalition for clinical research-self-monitoring of blood glucose. J Diabetes Sci Technol (2008) 1.81
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care (2003) 1.66
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther (2011) 1.57
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J Pediatr (2009) 1.54
Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. Environ Health Perspect (2008) 1.53
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care (2010) 1.50
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev (2004) 1.43
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes (2004) 1.37
Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med (2010) 1.37
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet (2011) 1.33
Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol (2005) 1.19
Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care (2003) 1.16
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care (2012) 1.11
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol (2002) 1.10
Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Part Fibre Toxicol (2010) 1.07
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther (2005) 1.07
Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control. Diabetes Technol Ther (2005) 1.05
Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care (2012) 1.04
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord (2011) 1.04
Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. Diabetes Educ (2006) 1.03
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes (2013) 1.02
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther (2005) 1.01
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res (2011) 0.98
North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. J Dent Educ (2011) 0.97
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
The prevention or delay of type 2 diabetes. Diabetes Care (2003) 0.95
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev (2009) 0.93
Exploring salivary proteomes in edentulous patients with type 2 diabetes. Mol Biosyst (2012) 0.92
Associations between arsenic species in exfoliated urothelial cells and prevalence of diabetes among residents of Chihuahua, Mexico. Environ Health Perspect (2014) 0.90
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin (2008) 0.89
Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. Mol Biosyst (2013) 0.88
Hemoglobin A1c to diagnose diabetes: why the controversy over adding a new tool? Clin Chem (2010) 0.87
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol (2013) 0.86
LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas (2014) 0.85
Effect of a viscous fiber bar on postprandial glycemia in subjects with type 2 diabetes. J Am Coll Nutr (2006) 0.85
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care (2009) 0.85
Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: A Cross-Sectional Study in Chihuahua, Mexico. Environ Health Perspect (2015) 0.84
Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin. Biomacromolecules (2014) 0.84
Screening for diabetes and prediabetes with proposed A1C-based diagnostic criteria: comment on Olson et al. Diabetes Care (2010) 0.83
Women's decision making about the use of hormonal and nonhormonal remedies for the menopausal transition. J Obstet Gynecol Neonatal Nurs (2003) 0.83
Adeno-associated virus-mediated expression of acid sphingomyelinase decreases atherosclerotic lesion formation in apolipoprotein E(-/-) mice. J Gene Med (2011) 0.83